Brokerages expect that Theravance Biopharma Inc (NASDAQ:TBPH) will report ($1.18) earnings per share for the current quarter, Zacks reports. Three analysts have provided estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.26) and the highest estimate coming in at ($1.02). Theravance Biopharma reported earnings per share of ($1.27) during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.1%. The firm is expected to issue its next quarterly earnings results on Tuesday, November 6th.
On average, analysts expect that Theravance Biopharma will report full-year earnings of ($4.41) per share for the current year, with EPS estimates ranging from ($4.70) to ($4.22). For the next fiscal year, analysts forecast that the company will report earnings of ($4.29) per share, with EPS estimates ranging from ($5.09) to ($3.72). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.20) by $0.44. Theravance Biopharma had a negative return on equity of 261.70% and a negative net margin of 640.07%. The business had revenue of $23.48 million during the quarter, compared to the consensus estimate of $9.97 million.
A number of analysts have issued reports on the company. ValuEngine raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 9th. Piper Jaffray Companies reissued an “overweight” rating and issued a $55.00 target price on shares of Theravance Biopharma in a research report on Wednesday, August 1st. Needham & Company LLC reissued a “buy” rating and issued a $40.00 target price on shares of Theravance Biopharma in a research report on Wednesday, August 1st. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Finally, BidaskClub raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Theravance Biopharma has an average rating of “Hold” and a consensus price target of $40.00.
In other news, EVP Bradford J. Shafer sold 31,300 shares of the firm’s stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $27.94, for a total value of $874,522.00. Following the completion of the transaction, the executive vice president now directly owns 127,606 shares of the company’s stock, valued at $3,565,311.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Renee D. Gala sold 43,743 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $26.79, for a total value of $1,171,874.97. The disclosure for this sale can be found here. Insiders sold 99,223 shares of company stock valued at $2,627,208 over the last three months. Company insiders own 6.90% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. UBS Group AG boosted its holdings in shares of Theravance Biopharma by 88.4% in the first quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 2,117 shares during the period. SG Americas Securities LLC bought a new position in shares of Theravance Biopharma in the first quarter worth $130,000. Xact Kapitalforvaltning AB bought a new position in shares of Theravance Biopharma in the first quarter worth $202,000. Royal Bank of Canada boosted its holdings in shares of Theravance Biopharma by 22.3% in the first quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 3,042 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Theravance Biopharma in the fourth quarter worth $419,000. 85.92% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:TBPH traded up $0.21 during trading hours on Wednesday, reaching $27.85. The stock had a trading volume of 123,994 shares, compared to its average volume of 306,450. The company has a debt-to-equity ratio of 6.52, a current ratio of 4.14 and a quick ratio of 3.95. Theravance Biopharma has a 12-month low of $21.27 and a 12-month high of $35.90. The company has a market capitalization of $1.50 billion, a P/E ratio of -5.11 and a beta of 1.80.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.
Featured Article: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.